ArticleNPJ precision oncology2026

KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors.

Iris Z Uras et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.